- DKK189.85bn
- DKK211.39bn
- €4.16bn
Brief: Novonesis Q2 Organic Pro Forma Sales Growth Of 10%
Brief: Novonesis Increases Outlook For 2024
Corrected: Small fire at Novonesis building extinguished, news agency Ritzau reports
Europe Research Roundup: Danske Bank, Entain, Halma
GS sees uneven recovery for European chemicals; ups Clariant, cuts Akzo
Europe Research Roundup: Hargreaves Lansdown, Segro, Umicore
Brief: Novonesis CFO: Slow Regulatory Approvals Are Main Obstacle To Growth
Novonesis jumps on outlook hike fuelled by rising biosolutions demand
Brief: Novozymes Says 2024 Outlook Of Pro Forma Organic Sales Growth Now Expected At Upper End Of 5-7% Range
Novonesis shares jump after Q1 household care growth beats expectations
Brief: Novonesis Maintains 2024 Outlook
Europe Research Roundup: Admiral, Auto Trader, BBVA
Novonensis expects 2024 adjusted EBITDA margin of 35% (updated)
Novonensis expects 2024 adjusted EBITDA margin of 35%
Brief: Novozymes Expects Organic Sales Growth Of 5-7% In 2024
Bernstein sees normalising consumer chemicals growth in 2024
Novo Nordisk-owner to expand in India this year
Brief: Novozymes: 2024 Outlook Wil Be Provided No Later Than March 31
Brief: Novozymes Q4 EBITDA DKK 1,320 Million